US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Supernus Pharmaceuticals, Inc.

< Previous 1 2 Next >
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces Second Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Participate in June Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces First Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Participate in March Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces Third Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Participate in September Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces Second Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SAGE SUPN
News headline image
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SAGE SUPN
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Announces First Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
News headline image
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SUPN
< Previous 1 2 Next >